



Viral Epidemiology Snapshot: August 14-20, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	227	1	0.4%
Flu B	227	0	0.0%
RSV	215	27	12.6%
CoV-2 PUI	820	186	22.7%
CoV-2 Surveillance	372	12	3.2%


Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	0
No Subtype	1
Pending subtype	0

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	214	10	4.7%
Coronavirus 229E	213	0	0.0%
Coronavirus HKU1	213	2	0.9%
Coronavirus NL63	213	0	0.0%
Coronavirus OC43	213	2	0.9%
Metapneumovirus	213	0	0.0%
Rhinovirus/Enterovirus	213	68	31.9%
Parainfluenza 1	213	8	3.8%
Parainfluenza 2	213	0	0.0%
Parainfluenza 3	213	0	0.0%
Parainfluenza 4	213	3	1.4%


Flu, RSV, & CoV-2 Trends



This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of Feb. '22) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of Oct. '21, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

